Clinical Trials Sponsored by Boehringer Mannheim

Total 2741 results

Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Spiriva® 18µg Once Daily in Chinese COPD Patients of Different Disease Severities

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

Hypertension
Boehringer Ingelheim

Terminated

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

Healthy
Boehringer Ingelheim

Completed

Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects

Healthy
Boehringer Ingelheim

Completed

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Telmisartan in Mild to Moderate Hypertensive Patients

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food

Healthy
Boehringer Ingelheim

Completed

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Hepatitis C, Chronic
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir

Healthy
Boehringer Ingelheim

Completed

Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke

Stroke
Boehringer Ingelheim

Completed

Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease

Parkinson Disease
Boehringer Ingelheim

Completed

Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)

Restless Legs Syndrome
Boehringer Ingelheim

Terminated

Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type

Alzheimer Disease
Boehringer Ingelheim

Completed

Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide

Hypertension
Boehringer Ingelheim

Completed

Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers

Healthy

3

Subscribe